Applied Biologics LLC: Company Profile

Background

Overview

Applied Biologics LLC is a fully integrated life sciences company specializing in the research, development, manufacturing, and distribution of medical technologies. Established in 2010 and headquartered in Scottsdale, Arizona, the company is dedicated to advancing regenerative medicine through innovative biologic solutions.

Mission and Vision

The company's mission is to advance regenerative medicine by providing innovative biologic solutions that enable healthcare providers to deliver optimal patient outcomes. Applied Biologics envisions becoming a leader in regenerative medicine products through continuous innovation and development of new technologies.

Primary Area of Focus

Applied Biologics focuses on regenerative medicine, particularly in the development and distribution of amniotic membrane-derived allografts for various clinical applications, including wound care, orthopedic procedures, and tissue healing.

Industry Significance

As a pioneer in amniotic membrane technology, Applied Biologics has established itself as a significant player in the regenerative medicine industry, offering products that address unmet medical needs and improve patient outcomes.

Key Strategic Focus

Core Objectives

Develop and commercialize innovative biologic products to enhance patient healing and recovery.

Expand market presence through strategic partnerships and collaborations.

Maintain high standards of quality and regulatory compliance in all operations.

Specific Areas of Specialization

Amniotic membrane-derived allografts for wound care and tissue repair.

Orthopedic applications, including sports medicine and spine surgery.

Chronic wound management and soft tissue defects.

Key Technologies Utilized

Aseptic recovery techniques for tissue procurement.

Proprietary processing methods to enhance product safety and efficacy.

Cryopreservation technologies for tissue storage and distribution.

Primary Markets Targeted

Hospitals and surgical centers.

Wound care clinics.

Orthopedic and sports medicine practices.

Government healthcare facilities, including VA Medical Centers and Department of Defense installations.

Financials and Funding

Funding History

Specific details regarding Applied Biologics' funding history, including total funds raised and recent funding rounds, are not publicly disclosed.

Notable Investors

Information about individual investors or venture capital firms involved with Applied Biologics is not publicly available.

Utilization of Capital

While specific utilization details are not disclosed, it is likely that capital has been allocated towards:

Research and development of new biologic products.

Expansion of manufacturing capabilities.

Regulatory compliance and quality assurance initiatives.

Marketing and sales efforts to increase market penetration.

Pipeline Development

Key Pipeline Candidates

XWRAP®: A dehydrated amniotic membrane allograft intended for use as a protective barrier and wound covering for acute and chronic wounds.

Stages of Development

XWRAP® is in the commercial stage, with ongoing clinical evaluations to further validate its efficacy and safety.

Target Conditions

Acute and chronic wounds, including diabetic ulcers, venous ulcers, arterial ulcers, pressure ulcers, and burns.

Anticipated Milestones

Completion of ongoing clinical trials.

Expansion of product indications.

Regulatory approvals for additional markets.

Technological Platform and Innovation

Proprietary Technologies

Advanced aseptic recovery and processing techniques to ensure tissue safety and product efficacy.

Cryopreservation methods for maintaining tissue viability during storage and transport.

Significant Scientific Methods

Utilization of amniotic membrane-derived allografts, leveraging their anti-inflammatory, anti-microbial, and anti-adhesion properties to promote healing.

Leadership Team

Executive Profiles

Edward Britt: Chief Executive Officer.

Background: Veteran entrepreneur with extensive experience in the medical device industry.

Contributions: Led the company through significant growth and product development milestones.

David Thompson: Chief Financial Officer.

Background: Financial strategist with a focus on healthcare companies.

Contributions: Oversees financial operations and strategic financial planning.

John Nieradka: Executive Vice President.

Background: Seasoned executive with a background in medical technologies.

Contributions: Responsible for overseeing product development and operational strategies.

Kimberlee Evans: Vice President of Sales.

Background: Sales leader with experience in the medical device sector.

Contributions: Drives sales strategies and manages the sales team to achieve revenue targets.

Samantha Montgomery: Reimbursement Manager.

Background: Expert in healthcare reimbursement processes.

Contributions: Ensures product reimbursement and assists healthcare providers with claim submissions.

Madeline Furbee: Operations Manager.

Background: Operations specialist with a focus on medical device manufacturing.

Contributions: Manages day-to-day operations to ensure efficient production and distribution.

Competitor Profile

Market Insights and Dynamics

The regenerative medicine market, particularly in the field of wound care and tissue repair, is experiencing significant growth due to an aging population and increasing prevalence of chronic wounds. Advancements in biologic products, such as amniotic membrane-derived allografts, are driving innovation and competition in this sector.

Competitor Analysis

Stryker Corporation: A leading medical technology company offering a range of products, including regenerative medicine solutions.

NuVasive, Inc.: Specializes in minimally invasive, procedurally integrated spine solutions, including biologic products.

Bioventus Inc.: Focuses on orthobiologics, providing bone healing solutions and regenerative therapies.

Strategic Collaborations and Partnerships

Applied Biologics has established partnerships with various healthcare providers and institutions to expand the reach of its products and enhance clinical outcomes. Notably, the company has been awarded a GSA Schedule 20 contract, enabling it to supply goods and services to federal government entities, including VA Medical Centers and Department of Defense installations.

Operational Insights

Applied Biologics differentiates itself through its vertically integrated approach, encompassing research, development, manufacturing, and distribution. This integration allows for stringent quality control and supply chain reliability, setting it apart from competitors who may rely on third-party manufacturers.

Strategic Opportunities and Future Directions

The company aims to expand its product portfolio by developing additional biologic solutions for various medical applications. Opportunities exist in international markets, where the demand for regenerative medicine is growing. Applied Biologics' commitment to innovation and quality positions it well to capitalize on these opportunities.